BNP Paribas Upgrades Prudential (NYSE:PUK) to Outperform

BNP Paribas upgraded shares of Prudential (NYSE:PUK) from a neutral rating to an outperform rating in a report released on Wednesday, Marketbeat reports.

Separately, StockNews.com downgraded shares of Prudential from a hold rating to a sell rating in a research report on Tuesday.

Prudential Price Performance

Shares of Prudential stock opened at $18.32 on Wednesday. Prudential has a 1 year low of $17.12 and a 1 year high of $28.59. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.03 and a quick ratio of 0.03. The company’s fifty day moving average is $19.08 and its two-hundred day moving average is $20.00.

Institutional Trading of Prudential

Several hedge funds have recently made changes to their positions in PUK. Glassman Wealth Services lifted its stake in shares of Prudential by 135.7% in the 4th quarter. Glassman Wealth Services now owns 1,183 shares of the financial services provider’s stock worth $27,000 after acquiring an additional 681 shares during the period. Principal Securities Inc. acquired a new stake in shares of Prudential in the 4th quarter worth $28,000. Russell Investments Group Ltd. lifted its stake in shares of Prudential by 369.2% in the 4th quarter. Russell Investments Group Ltd. now owns 1,370 shares of the financial services provider’s stock worth $31,000 after acquiring an additional 1,078 shares during the period. National Bank of Canada FI lifted its stake in shares of Prudential by 198.0% in the 4th quarter. National Bank of Canada FI now owns 2,101 shares of the financial services provider’s stock worth $45,000 after acquiring an additional 1,396 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Prudential in the 1st quarter worth $75,000. Institutional investors and hedge funds own 1.90% of the company’s stock.

Prudential Company Profile

Prudential plc, through its subsidiaries, provides life and health insurance, and asset management solutions to individuals in Asia and Africa. The company was founded in 1848 and is headquartered in Central, Hong Kong.